Literature DB >> 10209515

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

M C Honorati1, A Palareti, P Dolzani, C A Busachi, R Rizzoli, A Facchini.   

Abstract

The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti-HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses. A total of 3085 vaccine recipients of plasma-derived and recombinant vaccine have been followed for 10 years to determine the kinetics of anti-HBs production and to construct a mathematical model which could efficiently predict the anti-HBs level decline. The anti-HBs peak level was reached 68 days after the last dose of recombinant vaccine and 138 days after the last dose of plasma-derived vaccines. The age of vaccinees negatively influenced the anti-HBs levels and also the time necessary to reach the anti-HBs peak. A bilogarithmic mathematical model (log10 level, log10 time) of anti-HBs decay has been constructed on a sample of recombinant vaccine recipients and subsequently validated on different samples of recombinant or plasma-derived vaccine recipients. Age, gender, type of vaccine (recombinant or plasma-derived), number of vaccine doses (three or four) did not influence the mathematical model of antibody decay. The program can be downloaded at the site: http:@www2.stat.unibo.it/palareti/vaccine.htm . Introducing an anti-HBs determination obtained after the peak, the program calculates a prediction of individual anti-HBs decline and allows planning of an efficient booster policy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209515      PMCID: PMC1905208          DOI: 10.1046/j.1365-2249.1999.00866.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine.

Authors:  A Degrassi; E Mariani; M C Honorati; P Roda; R Miniero; M Capelli; A Facchini
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Scheduling of revaccination against hepatitis B virus.

Authors:  P Coursaget; B Yvonnet; W R Gilks; C C Wang; N E Day; J P Chiron; I Diop-Mar
Journal:  Lancet       Date:  1991-05-18       Impact factor: 79.321

Review 3.  Modern vaccines. Hepatitis.

Authors:  A Eddleston
Journal:  Lancet       Date:  1990-05-12       Impact factor: 79.321

4.  Decline of anti-HBs after hepatitis B vaccination and timing of revaccination.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

5.  Half-life of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination.

Authors:  F E Nommensen; S T Go; D M MacLaren
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

6.  Hepatitis B vaccination: protection for how long and against what?

Authors:  A J Hall
Journal:  BMJ       Date:  1993-07-31

7.  Construction and characterization of a Saccharomyces cerevisiae strain (RIT4376) expressing hepatitis B surface antigen.

Authors:  N Harford; T Cabezon; B Colau; A M Delisse; T Rutgers; M De Wilde
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

8.  Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months.

Authors:  C Goilav; H Prinsen; P Piot
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

9.  A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates.

Authors:  L Ding; M Zhang; Y Wang; S Zhou; W Kong; R A Smego
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

10.  [Detection of pre-S gene products in HBsAg carriers and in hepatitis B vaccines].

Authors:  G Gerken; M Manns; A Kyriatsoulis; G Hess; K H Meyer zum Büschenfelde
Journal:  Z Gastroenterol       Date:  1988-07       Impact factor: 2.000

View more
  15 in total

1.  Immune response against HBsAg vaccine.

Authors:  Maria Cristina Honorati; Andrea Facchini
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

2.  Prevention of Viral Hepatitis.

Authors:  Raymond S. Koff
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

3.  Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.

Authors:  Vincent Gajdos; Benoit Soubeyrand; Emmanuel Vidor; Patrick Richard; Julie Boyer; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin       Date:  2011-05-01

4.  Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

Authors:  Yunda Huang; Lily Zhang; Holly Janes; Nicole Frahm; Abby Isaacs; Jerome H Kim; David Montefiori; M Julie McElrath; Georgia D Tomaras; Peter B Gilbert
Journal:  Vaccine       Date:  2017-01-25       Impact factor: 3.641

5.  Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children.

Authors:  Cenk Aypak; Adnan Yüce; Hülya Yıkılkan; Süleyman Görpelioğlu
Journal:  Eur J Pediatr       Date:  2012-08-16       Impact factor: 3.183

Review 6.  Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.

Authors:  Jennifer A Whitaker; Nadine G Rouphael; Srilatha Edupuganti; Lilin Lai; Mark J Mulligan
Journal:  Lancet Infect Dis       Date:  2012-12       Impact factor: 25.071

7.  Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus.

Authors:  Mathieu Andraud; Olivier Lejeune; Jammbe Z Musoro; Benson Ogunjimi; Philippe Beutels; Niel Hens
Journal:  PLoS Comput Biol       Date:  2012-03-01       Impact factor: 4.475

8.  Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran.

Authors:  Behrouz Yazdanpanah; Mitra Safari; Shahrzad Yazdanpanah
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

Review 9.  Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update.

Authors:  Raymond S Koff
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.487

10.  Serologic control against hepatitis B virus among dental students of the University of Granada, Spain.

Authors:  M-T Arias-Moliz; L Rojas; F Liébana-Cabanillas; C Bernal; F Castillo; A Rodríguez-Archilla; A Castillo; J Liébana
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.